Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
https://doi.org/10.15829/1560-4071-2020-3809
Abstract
The article presents modern approaches to choosing a P2Y12 inhibitor as part of combined antithrombotic therapy in patients with acute coronary syndrome, depending on the indications for interventional treatment and the presence of comorbidities such as atrial fibrillation and diabetes.
Keywords
acute coronary syndrome,
percutaneous coronary intervention,
dual antiplatelet therapy,
prasugrel,
ticagrelor,
clopidogrel
Supporting agencies: The paper was supported by the pharmaceutical company Servier (France)
About the Authors
A. N. Golosova
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
S. V. Gatsura
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
E. A. Ulyanova
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
Zh. Yu. Dvoryanchikova
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
References
1. Boytsov SA, Demkina AE, Oshchepkova EV, Dolgusheva YuA. Progress and Problems of Practical Cardiology at the Present Stage. Kardiologiia. 2019;59(3):53-9. (In Russ.) doi:10.18087/cardio.2019.3.10242.
2. Samorodskaya LV, Starinskaya MA, Semyonov VYu, Kakorina EP. Nosologically and age-stratified mortality structure from cardiovascular diseases in the years 2006 and 2014. Russ J Cardiol. 2016;(6):7-14. (In Russ.) doi:10.15829/1560-4071-2016-6-7-14.
3. Federal state statistics service. http//www.gks.ru (July 02, 2018). (In Russ.) Федеральная служба государственной статистики. http//www.gks.ru (02 Июля 2018г).
4. Population Division. Department of Economic and Social Affairs. United Nations. Revision of World Population Prospects. https://esa.un.org/unpd/wpp/
5. Schomig A, Neumann F, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334(17):1084-9. doi:10.1056/NEJM199604253341702.
6. Leon M, Baim D, Popma J, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339(23):1665-71. doi:10.1056/NEJM199812033392303.
7. Gawaz M, Ott I, Neumann F. Surface expression of platelet membrane glycoproteins following coronary stenting: effect on subacute stent thrombosis? Circulation. 1994;90 (suppl I):I-552.
8. Tschoepe D, SchultheiB H, Kolarov P, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation.1993;88:37-42. doi:10.1161/01.cir.88.1.37.
9. Urban P, Macaya C, Rupprecht H, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998;98:2126-32. doi:10.1161/01.cir.98.20.2126.
10. Yeh R, Kereiakes D, Steg P, et al. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015;65:2211-21. doi:10.1016/j.jacc.2015.03.003.
11. Bertrand M, Legrand V, Boland J, et al. Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary Stenting The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation. 1998;98:1597-603. doi:10.1161/01.cir.98.16.1597.
12. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001;86(1):222-32. doi:10.1055/s-0037-1616220.
13. Quinn M, Fitzgerald D. Ticlopidine and Clopidogrel. Circulation. 1999; 100(15):1667-72. doi:10.1161/01.cir.100.15.1667.
14. Yusuf S, Zhao F, Mehta S, et al. Effects of Clopidogrel in Addition to Aspirin in Patients With Acute Coronary Syndromes Without ST-segment Elevation. N Engl J Med. 2001 Aug 16;345(7):494-502. doi:10.1056/NEJMoa010746.
15. Gallon M. COMMIT/CCS-2 studies. Lancet. 2006;368(9536):642. doi:10.1016/S0140-6736(06)69235-0.
16. Sabatine M, Cannon C, Gibson C, et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179-89. doi:10.1056/NEJMoa050522.
17. Mehta S, Tanguay J, Eikelboom J, et al. Double-dose Versus Standard-Dose Clopidogrel and High-Dose Versus Low-Dose Aspirin in Individuals Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes (CURRENT-OASIS 7): A Randomised Factorial Trial. Lancet. 2010;376(9748):1233-43. doi:10.1016/S0140-6736(10)61088-4.
18. Valgimigli M, Bueno H, Byrne R, et al. 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Developed in Collaboration With EACTS: The Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60. doi:10.1093/eurheartj/ehx419.
19. Berwanger O, Nicolau J, Carvalho A, et al. Ticagrelor Versus Clopidogrel After Fibrinolytic Therapy in Patients With ST-elevation Myocardial Infarction: Rationale and Design of the Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Thrombolysis (TREAT) Trial. Am Heart J. 2018;202:89-96.
20. Koul S, Smith J, Schersten F, et al. Effect of Upstream Clopidogrel Treatment in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Eur Heart J. 2011;32(23):2989-97. doi:10.1093/eurheartj/ehr202.
21. Zeymer U, Arntz H, Mark B, et al. Efficacy and Safety of a High Loading Dose of Clopidogrel Administered Prehospitally to Improve Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The Randomized CIPAMI Trial. Clin Res Cardiol. 2012;101(4):305-12. doi:10.1007/s00392-011-0393-1.
22. Dorler J, Edlinger M, Alber H, et al. Clopidogrel Pre-Treatment Is Associated With Reduced In-Hospital Mortality in Primary Percutaneous Coronary Intervention for Acute ST-elevation Myocardial Infarction. Eur Heart J. 2011 ;32(23):2954-61. doi: 10.1093/eurheartj/ehr360.
23. Muller I, Seyfarth M, Rudiger S, et al. Effect of a High Loading Dose of Clopidogrel on Platelet Function in Patients Undergoing Coronary Stent Placement. Heart. 2001;85(1):92-3. doi:10.1136/heart.85.1.92.
24. Farid N, McIntosh M, Garofolo F, et al. Determination of the Active and Inactive Metabolites of Prasugrel in Human Plasma by Liquid chromatography/tandem Mass Spectrometry. Rapid Commun Mass Spectrom. 2007;21:169-79. doi:101002/rcm.2813.
25. Farid N, Kurihara A, Wrighton SA. Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans. J Clin Pharmacol. 2010;50(2):126-42. doi:10.1177/0091270009343005.
26. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. doi:10.1056/NEJMoa0706482.
27. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999-1010. doi:10.1056/NEJMoa1308075.
28. Neumann FJ, Sousa-Uva M, Ahlsson A. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi:10.1093/eurheartj/ehy394.
29. Instructions for medical use of the drug Effient®. Registration certificate LP-000675 from 28.09.11 (reissued 05.07.2017). (In Russ.)
30. Instructions for medical use of the drug Brilinta® (film-coated tablets, 90 mg), subject to changes 1-6. Registration certificate LP-001059 from 27.10.2011 (reissued 02.11.2016). (In Russ.)
31. Schulz-Schupke S, Byrne R, Ten Berg M, et al. ISAR-SAFE: A Randomized, Double-Blind, Placebo-Controlled Trial of 6 vs. 12 Months of Clopidogrel Therapy After Drug-Eluting Stenting. Eur Heart J. 2015;36:1252-63. doi:101093/eurheartj/ehu523.
32. Gilard M, Barragan P, Noryani A, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65:777-86. doi:10.1016/j.jacc.201411.008.
33. Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086-97. doi: 101016/j.jacc.2014.09.008.
34. Valgimigli M, Campo G, Monti M, et al. Short-versus long-term duration of dualantiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015-26. doi: 10.1161/CIRCULATIONAHA.111.071589.
35. Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Multicenter Randomized PRAGUE-18 Study. Circulation. Circulation . 2016;134(21):1603-1612. doi:10.1161/CIRCULATIONAHA.116.024823.
36. Motovska Z, Hlinomaz O, Kala P, et al. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor. J Am Coll Cardiol. 2018;71(4):371-81. doi:10.1016/j.jacc.2017.11.008.
37. Krishnamurthy A, Keeble C, Anderson M, et al. Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention. Open Heart. 2019;6(1):e000951. doi:10.1136/openhrt-2018-000951.
38. Mehran R, Pocock S, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556-66. doi:10.1016/j.jacc.2009.09.076.
39. Olier I, Sirker A, Hildick-Smith DJR, et al. Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. Heart. 2018;104(20):1683-90. doi:10.1136/heartjnl-2017-312366.
40. Schupke S, Neumann F, Menichelli M, et al. Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524-1534. doi:10.1056/NEJMoa1908973.
41. Yang H, Tang B, Xu C, et al. Ticagrelor Versus Prasugrel for the Treatment of Patients With Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Diabetes Ther. 2019 Feb;10(1):81-93. doi:101007/s13300-018-0537-7.
Review
For citations:
Golosova A.N., Gatsura S.V., Ulyanova E.A., Dvoryanchikova Zh.Yu. Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention. Russian Journal of Cardiology. 2020;25(7):3809. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3809
Views:
717
Email this article 